This suggests that in MC38 or CT26 models at least, blocking the activity of TGF-β1 emanating from GARP-expressing Tregs triggers tumor regression by inducing or re-invigorating inflammatory and cytolytic activities of anti-tumor CD8+ T cells that are already present in the tumor. This evidence concerns the gene CD8A and neoplasm.